BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38479611)

  • 1. Retrospective analysis of multiple myeloma drug use in cutaneous toxicity of monoclonal gammopathy of undetermined significance.
    Gordon ER; Chen C; Adeuyan O; Lapolla BA; Trager MH; Fahmy LM; Schreidah CM; Wetter DA; Geskin LJ
    J Am Acad Dermatol; 2024 Jul; 91(1):129-130. PubMed ID: 38479611
    [No Abstract]   [Full Text] [Related]  

  • 2. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
    Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
    Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma.
    Greenberg AJ; Rajkumar SV; Larson DR; Dispenzieri A; Therneau TM; Colby CL; Phelps TK; Kumar SK; Katzmann JA; Kyle RA; Slager SL; Vachon CM
    Br J Haematol; 2012 May; 157(4):472-5. PubMed ID: 22629552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retrospective analysis of progression to multiple myeloma or related disorders in 114 patients with monoclonal gammopathy of undetermined significance in a single institute].
    Yokota S; Urasaki Y; Nakamura Y; Bessho M
    Rinsho Ketsueki; 2012 Mar; 53(3):303-9. PubMed ID: 22499046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.
    Schmitz MF; Otten HG; Franssen LE; van Dorp S; Strooisma T; Lokhorst HM; van de Donk NW
    Haematologica; 2014 Dec; 99(12):1846-53. PubMed ID: 25193963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.
    Wadhera RK; Kyle RA; Larson DR; Dispenzieri A; Kumar S; Lazarus HM; Rajkumar SV
    Blood; 2011 Sep; 118(11):2985-7. PubMed ID: 21765020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France).
    Cabrera Q; Macro M; Hebert B; Cornet E; Collignon A; Troussard X
    Cancer Epidemiol; 2014 Aug; 38(4):354-6. PubMed ID: 24880205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.
    Chang SH; Luo S; Thomas TS; O'Brian KK; Colditz GA; Carlsson NP; Carson KR
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma.
    Neriishi K; Nakashima E; Suzuki G
    Br J Haematol; 2003 May; 121(3):405-10. PubMed ID: 12716362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
    Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
    Greenberg AJ; Rajkumar SV; Vachon CM
    Blood; 2012 Jun; 119(23):5359-66. PubMed ID: 22354002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.
    Sverrisdóttir IS; Lund SH; Turesson I; Björkholm M; Goldin LR; Landgren O; Kristinsson SY
    Br J Haematol; 2019 Jul; 186(1):37-44. PubMed ID: 30906990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
    Stelmach-Gołdyś A; Czarkowska-Paczek B
    Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA
    Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
    Go RS; Gundrum JD; Neuner JM
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
    Cowan A; Ferrari F; Freeman SS; Redd R; El-Khoury H; Perry J; Patel V; Kaur P; Barr H; Lee DJ; Lightbody E; Downey K; Argyelan D; Theodorakakou F; Fotiou D; Liacos CI; Kanellias N; Chavda SJ; Ainley L; Sandecká V; Pospíšilová L; Minarik J; Jungova A; Radocha J; Spicka I; Nadeem O; Yong K; Hájek R; Kastritis E; Marinac CR; Dimopoulos MA; Get G; Trippa L; Ghobrial IM
    Lancet Haematol; 2023 Mar; 10(3):e203-e212. PubMed ID: 36858677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.